Colorectal hepatic metastasis: Evolving therapies

World Journal of Hepatology

Volumn 6, Issue 7, 2014, Pages 453-463

  Macedo, Francisco Igor B ^a   Makarawo, Tafadzwa ^a  

^a PROVIDENCE HOSPITAL   (United States)

Author keywords

5 fluorouracil leucovorin and oxaliplatin; Chemotherapy; Colorectal cancer; Hepatectomy; Hepatic metastasis; Survival

Indexed keywords

EID: 84905995411     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i7.453     Document Type: Review

References (104)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
2. Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210: 127-138 [PMID: 2667471 DOI: 10.1097/00000658-1989080 00-00001]
3. Mohammad WM, Balaa FK. Surgical management of colorectal liver metastases. Clin Colon Rectal Surg 2009; 22: 225-232 [PMID: 21037813 DOI: 10.1055/s-0029-1242462]
4. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-1246 [PMID: 2253003 DOI: 10.1002/bjs.1800771115]
5. Kamel IR, Fishman EK. Recent advances in CT imaging of liver metastases. Cancer J 2004; 10: 104-120 [PMID: 15130270 DOI: 10.1097/00130404-200403000-00006]
6. Braga L, Guller U, Semelka RC. Modern hepatic imaging. Surg Clin North Am 2004; 84: 375-400 [PMID: 15062651 DOI: 10.1016/S0039-6109(03)00227-5]
7. Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013; 15: 91-103 [PMID: 23297719 DOI: 10.1111/j. 1477-2574.2012.00 557.x]
8. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007; 13: 5025-5029 [PMID: 17854148]
9. Schmidt GP, Baur-Melnyk A, Haug A, Utzschneider S, Becker CR, Tiling R, Reiser MF, Hermann KA. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur Radiol 2009; 19: 1366-1378 [PMID: 19190917 DOI: 10.1007/s00330-008-1289-y]
10. Truant S, Huglo D, Hebbar M, Ernst O, Steinling M, Pruvot FR. Prospective evaluation of the impact of [18F] fluoro-2-deoxy- D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92: 362-369 [PMID: 15672427 DOI: 10.1002/bjs.4843]
11. Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol 2011; 2011: 285840 [PMID: 22312501 DOI: 10.1155/2011/285840]
12. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321 [PMID: 10493478 DOI: 10.1097/00000658-199909000-00004]
13. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262 [PMID: 8608500]
14. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg 2005; 140: 183-189 [PMID: 15724001 DOI: 10.1001/archsurg.140.2.183]
15. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-299 [PMID: 10472930 DOI: 10.1016/S1072-7515 (99)00089-7]
16. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766 [PMID: 12035031 DOI: 10.1097/00000658-200206000-00002]
17. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825; discussion 825-827 [PMID: 15166961 DOI: 10.1097/01.sla.0000128305.90650.71]
18. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13: 1261-1268 [PMID: 16947009 DOI: 10.1245/s104 34-006-9023-y]
19. Cady B, Jenkins RL, Steele GD, Lewis WD, Stone MD, Mc-Dermott WV, Jessup JM, Bothe A, Lalor P, Lovett EJ, Lavin P, Linehan DC. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998; 227: 566-571 [PMID: 9563547 DOI: 10.1097/00000658-199804000-00019]
20. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71 [PMID: 7740812 DOI: 10.1007/BF00316981]
21. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 Suppl 3: iii1-iii8 [PMID: 16835351 DOI: 10.1136/gut.2006.098053]
22. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch- Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]
23. Hillingsø JG, Wille-Jørgensen P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer--a systematic review. Colorectal Dis 2009; 11: 3-10 [PMID: 18637099 DOI: 10.1111/j.1463-1318.2008.01625.x]
24. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520; discussion 520-522 [PMID: 8857855 DOI: 10.1097/00000658-199610000-00009]
25. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 657-658 [PMID: 15383792]
26. Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovannini I, Barone C. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg 2007; 11: 318-324 [PMID: 17458605 DOI: 10.1007/s11605-006-0070-2]
27. Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002; 131: 433-442 [PMID: 11935134 DOI: 10.1067/msy.2002.122374]
28. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, Jarnagin WR, Patel D, D'Angelica M. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27: 3465-3471 [PMID: 19470932 DOI: 10.1200/JCO.2008.20.1301]
29. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010; 21 Suppl 5: v93-v97 [PMID: 20555112 DOI: 10.1093/annonc/mdq222]
30. Ito K, Govindarajan A, Ito H, Fong Y. Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 2010; 16: 103-110 [PMID: 20404606 DOI: 10.1097/PPO.0b013e3181d7e8e5]
31. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia- Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013; 15: 106-115 [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558.x]
32. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/JCO.2006.09.0928]
33. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152 [PMID: 17630037 DOI: 10.1016/S0140-6736(07)61087-3]
34. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142 [PMID: 17630036 DOI: 10.1016/S0140-6736(07)61086-1]
35. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447; discussion 447-450 [PMID: 15319715 DOI: 10.1097/01.sla.0000138076.72547.b1]
36. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H, Yamamoto J. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003; 46: S22-S31 [PMID: 14530655]
37. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J, Imamura H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231: 487-499 [PMID: 10749608 DOI: 10.1097/00000658-2 00004000-00006]
38. Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995; 222: 426-434; discussion 434-437 [PMID: 7574924]
39. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multiinstitutional analysis of 1669 patients. Ann Surg 2009; 250: 440-448 [PMID: 19730175]
40. de Jong MC, Mayo SC, Pulitano C, Lanella S, Ribero D, Strub J, Hubert C, Gigot JF, Schulick RD, Choti MA, Aldrighetti L, Mentha G, Capussotti L, Pawlik TM. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009; 13: 2141-2151 [PMID: 19795176 DOI: 10.1007/s11605-009-1050-0]
41. Buell JF, Thomas MT, Rudich S, Marvin M, Nagubandi R, Ravindra KV, Brock G, McMasters KM. Experience with more than 500 minimally invasive hepatic procedures. Ann Surg 2008; 248: 475-486 [PMID: 18791368]
42. Mala T, Edwin B, Rosseland AR, Gladhaug I, Fosse E, Mathisen O. Laparoscopic liver resection: experience of 53 procedures at a single center. J Hepatobiliary Pancreat Surg 2005; 12: 298-303 [PMID: 16133696 DOI: 10.1007/s00534-005-0974-3]
43. Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 2010; 17: 492-501 [PMID: 19856028 DOI: 10.1245/s10434-009-0781-1]
44. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061; discussion 1061-1064 [PMID: 15570210 DOI: 10.1097/01.sla.0000145964.08365.01]
45. Gallagher DJ, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, D'Angelica M, Fong Y, Jarnagin WR, Allen PJ, Kemeny N. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009; 16: 1844-1851 [PMID: 19224284 DOI: 10.1245/s10434-009-0348-1]
46. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, Rougier P, Nordlinger B. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7 [PMID: 16371728 DOI: 10.1097/01.sla.0000193603.26265.c3]
47. Abdalla EK, Bauer TW, Chun YS, D'Angelica M, Kooby DA, Jarnagin WR. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford) 2013; 15: 119-130 [PMID: 23297723 DOI: 10.1111/j.1477-2574.2012.00597.x]
48. Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol 2009; 16: 1208-1211 [PMID: 19214636 DOI: 10.1245/s10434-009-032 8-5]
49. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911 [PMID: 18794541 DOI: 10.1200/JCO. 2008.17.37 81]
50. Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002; 21: 592
51. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982 [PMID: 17075115 DOI: 10.1200/JCO.2006.06.8353]
52. Reddy SK, Zorzi D, Lum YW, Barbas AS, Pawlik TM, Ribero D, Abdalla EK, Choti MA, Kemp C, Vauthey JN, Morse MA, White RR, Clary BM. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol 2009; 16: 1809-1819 [PMID: 18979139 DOI: 10.1245/s10434-008-0181-y]
53. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1964-1970 [PMID: 19567451 DOI: 10.1093/annonc/mdp236]
54. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
55. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527 [PMID: 19636327]
56. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65 [PMID: 12506171]
57. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048 [PMID: 18003960 DOI: 10.1056/NEJMoa071834]
58. Lucke B, Breedis C, Woo ZP, Berwick L, Nowell P. Differential growth of blood-borne metastatic tumors in liver and lung (experiments with rabbit V-2 carcinoma). Am J Pathol 1951; 27: 729-730 [PMID: 14846956]
59. Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 1974; 75: 589-596 [PMID: 4840805]
60. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119-125 [PMID: 11951209 DOI: 10.1053/sonc.2002.31679]
61. Allen PJ, Stojadinovic A, Ben-Porat L, Gonen M, Kooby D, Blumgart L, Paty P, Fong Y. The management of variant arterial anatomy during hepatic arterial infusion pump placement. Ann Surg Oncol 2002; 9: 875-880 [PMID: 12417509 DOI: 10.1007/BF02557524]
62. Stratmann SL. Hepatic artery chemotherapy in the management of colorectal metastases. Proc (Bayl Univ Med Cent) 2002; 15: 376-379 [PMID: 16333468]
63. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987; 5: 1836-1840 [PMID: 3681370]
64. Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1236-1241 [PMID: 19233901 DOI: 10.1093/annonc/mdn769]
65. Kemeny N, Seiter K, Conti JA, Cohen A, Bertino JR, Sigurdson ER, Botet J, Chapman D, Mazumdar M, Budd AJ. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer 1994; 73: 1134-1142 [PMID: 8313315 DOI: 10.1002/1097-0142(19940215)73:4<1134::AIDCNCR2820730403> 3.0.CO;2-V]
66. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649-5654 [PMID: 18065736 DOI: 10.1200/JCO.2007.12.1764]
67. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395-1403 [PMID: 16505413 DOI: 10.1200/JCO.2005.03.8166]
68. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, Stockman J, Fong Y, Jarnagin W, Bertino J, Tong W, Paty P. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19: 2687-2695 [PMID: 11352961]
69. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048 [PMID: 10615075 DOI: 10.1056/NEJM199912303412702]
70. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60: 1552-1563 [PMID: 15590187 DOI: 10.1016/j.ijrobp.2004.09.004]
71. Gulec SA, Pennington K, Wheeler J, Barot TC, Suthar RR, Hall M, Schwartzentruber D. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo- SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial. Am J Clin Oncol 2013; 36: 455-460 [PMID: 22643569 DOI: 10.1097/COC. 0b013e3182 546c50]
72. Wasan H, Kennedy A, Coldwell D, Sangro B, Salem R. Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases. Am J Clin Oncol 2012; 35: 293-301 [PMID: 21278562 DOI: 10.1097/COC.0b013e3182005747]
73. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12: 1711-1720 [PMID: 11843249 DOI: 10.1023/A:1013569329846]
74. Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103: 324-331 [PMID: 20628388 DOI: 10.1038/sj.bjc.6605770]
75. Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M, Geschwind JF, Salem R. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F] fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16: 1641-1651 [PMID: 16371530 DOI: 10.1097/01.RVI.0000179815.44868.66]
76. Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol 2013; 24: 1209-1217 [PMID: 23885916 DOI: 10.1016/j. jvir.2013.05.055]
77. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecanloaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395 [PMID: 22493375]
78. Martin RC, Scoggins CR, Tomalty D, Schreeder M, Metzger T, Tatum C, Sharma V. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 2012; 16: 1531-1538 [PMID: 22528576 DOI: 10.1007/s11605-012-1892-8]
79. Fiorentini G, Poddie DB, Cantore M, Giovanis P, Guadagni S, De Giorgi U, Cariello A, Dazzi C, Turci D. Locoregional therapy for liver metastases from colorectal cancer: the possibilities of intraarterial chemotherapy, and new hepaticdirected modalities. Hepatogastroenterology 2001; 48: 305-312 [PMID: 11379296]
80. Bower M, Metzger T, Robbins K, Tomalty D, Válek V, Boudnỳ J, Andrasina T, Tatum C, Martin RC. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multiinstitutional study. HPB (Oxford) 2010; 12: 31-36 [PMID: 20495642 DOI: 10.1111/j.1477-2574.2009.00117.x]
81. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-3775 [PMID: 15365073 DOI: 10.1200/JCO.2004.03.104]
82. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998; 43: 141-154 [PMID: 9654872]
83. Ng KM, Chua TC, Saxena A, Zhao J, Chu F, Morris DL. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. Ann Surg Oncol 2012; 19: 1276-1283 [PMID: 21913018 DOI: 10.1245/s10434-011-2025-4]
84. Seifert JK, Springer A, Baier P, Junginger T. Liver resection or cryotherapy for colorectal liver metastases: a prospective case control study. Int J Colorectal Dis 2005; 20: 507-520 [PMID: 15973545 DOI: 10.1007/s00384-004-0723-0]
85. Rivoire M, De Cian F, Meeus P, Négrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002; 95: 2283-2292 [PMID: 12436433 DOI: 10.1002/cncr. 10973]
86. Allen PJ, D'Angelica M, Hodyl C, Lee J, You YJ, Fong Y. The effects of hepatic cryosurgery on tumor growth in the liver. J Surg Res 1998; 77: 132-136 [PMID: 9733599 DOI: 10.1006/jsre.1998.5365]
87. Bhardwaj N, Strickland AD, Ahmad F, Atanesyan L, West K, Lloyd DM. A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. Pathology 2009; 41: 168-172 [PMID: 19152189 DOI: 10.1080/00313020802579292]
88. Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1999; 23: 109-113; discussion 113-114 [PMID: 9880417 DOI: 10.1007/PL00013173]
89. Primrose JN. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut 2002; 50: 1-5 [PMID: 11772955 DOI: 10.1136/gut.50.1.1]
90. Rocha FG, D'Angelica M. Treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, and microwave coagulation. J Surg Oncol 2010; 102: 968-974 [PMID: 21166000 DOI: 10.1002/jso.21720]
91. Hompes D, Prevoo W, Ruers T. Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. Cancer Imaging 2011; 11: 23-30 [PMID: 21435988]
92. Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009; 45: 1748-1756 [PMID: 19356924 DOI: 10.1016/j.ejca.2009.03.012]
93. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28: 493-508 [PMID: 19841322 DOI: 10.1200/JCO.2009.23.4450]
94. Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF. Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol 2002; 8: 624-630 [PMID: 12174368]
95. Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, De Wever I, Michel L. Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002; 89: 1206-1222 [PMID: 12296886 DOI: 10.1046/j.1365-2168.2002.02168.x]
96. Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, Poston G. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis 2011; 13: e252-e265 [PMID: 21689362 DOI: 10.1111/j.1463-1318.2011.02695.x]
97. Iannitti DA, Martin RC, Simon CJ, Hope WW, Newcomb WL, McMasters KM, Dupuy D. Hepatic tumor ablation with clustered microwave antennae: the US Phase II trial. HPB (Oxford) 2007; 9: 120-124 [PMID: 18333126 DOI: 10.1080/136 51820701222677]
98. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010; 17: 171-178 [PMID: 19707829 DOI: 10.1245/s10434-009-0686-z]
99. Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005; 236: 132-139 [PMID: 15987969 DOI: 10.1148/radiol.2361031249]
100. Shibata T, Niinobu T, Ogata N. Comparison of the effects of in-vivo thermal ablation of pig liver by microwave and radiofrequency coagulation. J Hepatobiliary Pancreat Surg 2000; 7: 592-598 [PMID: 11180892 DOI: 10.1007/s005340070009]
101. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 2011; 117: 4060-4069 [PMID: 21432842 DOI: 10.1002/cncr.25997]
102. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R. Outcome in a prospective phase II trial of medically inoperable stage I non-smallcell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27: 3290-3296 [PMID: 19414667 DOI: 10.1200/JCO.2008.21.5681]
103. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-1076 [PMID: 20233825 DOI: 10.1001/jama.2010.261]
104. van der Pool AE, Méndez Romero A, Wunderink W, Heijmen BJ, Levendag PC, Verhoef C, Ijzermans JN. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010; 97: 377-382 [PMID: 20095016 DOI: 10.1002/bjs.6895]